Advancing the Science of Immuno-Oncology

At Aptevo, we are advancing a new generation of targeted immunotherapies designed to harness the power of the immune system with precision. Our work is grounded in deep expertise in multispecific antibody engineering, with a focus on developing therapies for patients facing difficult-to-treat cancers and areas of significant unmet medical need.

Our therapeutic candidates are purpose-built with both innovation and clinical practicality in mind — designed to engage multiple immune pathways while supporting potential combinability with existing standards of care and emerging treatment technologies. Through this approach, Aptevo is working to expand what may be possible for patients with cancer.

Management Team

Jeff-Lamothe

Jeff Lamothe

President and Chief Executive Officer

Daphne-Taylor

Daphne Taylor

Senior Vice President and Chief Financial Officer

Dirk-Huebner

Dirk Huebner, M.D.,

Senior Vice President and Chief Medical Officer

Mary-Janatpour

Mary J. Janatpour, PhD

Senior Vice President and Chief Scientific Officer

SoYoung-Kwon

SoYoung Kwon

Senior Vice President and General Counsel, Business Development and Corporate Affairs

Miriam-Weber-Miller

Miriam Weber Miller

Vice President, Investor Relations and Corporate Communications

Board of Directors

Marvin-White

Marvin L. White

Executive Chairman

John-Niederhuber

John E. Niederhuber, M.D.

Board Member

Dan-Abdun-Nabi

Daniel J. Abdun-Nabi

Board Member

Grady-Grant

Grady Grant, III

Board Member

Zsolt-Harsyani

Zsolt Harsanyi, Ph.D.

Board Member

Barbara-Lopez-Kunz

Barbara Lopez Kunz

Board Member

Jeff-Lamothe

Jeff Lamothe

President and Chief Executive Officer